𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer

✍ Scribed by Rafael Rosell; Enriqueta Felip

Book ID
114105296
Publisher
Elsevier Science
Year
2001
Tongue
English
Weight
946 KB
Volume
28
Category
Article
ISSN
0093-7754

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Vorinostat increases carboplatin and pac
Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells
✍ Taofeek K. Owonikoko; Suresh S. Ramalingam; Beatriz Kanterewicz; Trent E. Balius πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 French βš– 533 KB

## Abstract We observed a 53% response rate in non‐small cell lung cancer (NSCLC) patients treated with vorinostat plus paclitaxel/carboplatin in a Phase I trial. Studies were undertaken to investigate the mechanism (s) underlying this activity. Growth inhibition was assessed in NSCLC cells by MTT